You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

Details for New Drug Application (NDA): 205786


✉ Email this page to a colleague

« Back to Dashboard


NDA 205786 describes ISENTRESS, which is a drug marketed by Msd Sub Merck and is included in three NDAs. It is available from nine suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ISENTRESS profile page.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.
Summary for 205786
Tradename:ISENTRESS
Applicant:Msd Sub Merck
Ingredient:raltegravir potassium
Patents:2
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 205786
Generic Entry Date for 205786*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205786
Mechanism of ActionHIV Integrase Inhibitors
Medical Subject Heading (MeSH) Categories for 205786
Suppliers and Packaging for NDA: 205786
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ISENTRESS raltegravir potassium POWDER;ORAL 205786 NDA Merck Sharp & Dohme LLC 0006-3603 0006-3603-60 60 PACKET in 1 CARTON (0006-3603-60) / 1 GRANULE, FOR SUSPENSION in 1 PACKET (0006-3603-01)
ISENTRESS raltegravir potassium POWDER;ORAL 205786 NDA Merck Sharp & Dohme LLC 0006-3603 0006-3603-61 60 PACKET in 1 CARTON (0006-3603-61) / 1 GRANULE, FOR SUSPENSION in 1 PACKET (0006-3603-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 100MG BASE/PACKET
Approval Date:Dec 20, 2013TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Apr 3, 2024Product Flag?Substance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Sep 11, 2029Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 205786

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.